Clinical Trials

Showing 381 - 400 of 519 trials
Title Investigatorsort icon Disease(s)
A Phase II Study of LEE011 plus MEK162 in Patients with NRAS-Mutant Melanoma
[Protocol 13-102]
Postow, Michael
  • Melanoma
A Phase Ib Study of AEB071 and MEK162 in Patients with Advanced Uveal Melanoma
[Protocol 13-172]
Postow, Michael
  • Melanoma
    • Melanoma of the Eye
A Study Analyzing Patients Treated for Wiskott-Aldrich Syndrome Since 1990
Newly Diagnosed & Relapsed/Refractory
[Protocol 14-066]
Prockop, Susan
  • Hematology
    • Hematologic Disorders
Expanded Access of Prochymal Infusion for the Treatment of Pediatric Patients with Acute Refractory GVHD
[Protocol 09-072]
Prockop, Susan
  • Blood and Marrow Transplantation
    • Transplantation
Mastectomy Reconstruction Outcomes Consortium (MROC) Study
[Protocol 11-175]
Pusic, Andrea
  • Breast Cancer
  • Survivorship
Development and Validation of a New Patient-Reported Outcome Instrument on the Impact of Altered Facial Appearance Following Oncologic Head and Neck Resection and Reconstruction
[Protocol 07-098]
Pusic, Andrea
  • Head & Neck Cancer
  • Survivorship
A Phase I Study of Ruxolitinib and Decitabine in Patients with Myeloproliferative Neoplasms in Accelerated or Blast Phase
[Protocol 14-175]
Rampal, Raajit
  • Leukemia
    • Acute Myelocytic Leukemia
    • Acute Myelogenous Leukemia
    • Myeloproliferative Neoplasm
A Phase III Study Comparing Pegylated Interferon Alfa-2a (PEGASYS) with Hydroxyurea in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera
[Protocol 13-188]
Rampal, Raajit
  • Hematology
    • Hematologic Disorders
A Phase Ib Study of ARN-509 plus Everolimus in Men with Progressive Metastatic Castration-Resistant Prostate Cancer After Abiraterone Therapy
[Protocol 13-025]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer
[Protocol 11-182]
Rathkopf, Dana
  • Prostate Cancer
    • Localized Disease
A Phase IA/B Study of CC-115 in Castration-Resistant Prostate Cancer
[Protocol 12-080]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase II Study of MLN0128 in Men with Castration-Resistant Prostate Cancer
[Protocol 13-143]
Rathkopf, Dana
  • Prostate Cancer
    • Metastatic Disease after Hormone-Reducing Therapy
A Phase III Study of ARN-509 versus Placebo in Men with Non-Metastatic Castration-Resistant Prostate Cancer
[Protocol 13-243]
Rathkopf, Dana
  • Prostate Cancer
    • Rising PSA After Primary Therapy
A Phase II Study of Temozolomide Alone and with Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors
[Protocol 13-194]
Reidy-Lagunes, Diane
  • Hepatobiliary
    • Pancreatic Cancer
  • Upper Gastrointestinal
    • Neuroendocrine
    • Pancreatic Cancer
A Phase I/II Study of the ALK Inhibitor CH5424802 in Patients with ALK-Rearranged Non-Small Cell Lung Cancer
[Protocol 12-113]
Riely, Gregory
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase I/II Study of Crizotinib and Ganetespib (STA-9090) in ALK-Positive Lung Cancers
[Protocol 12-015]
Riely, Gregory
  • Lung Cancer
  • Lung Cancer, Non-Small Cell
    • Lung Adenocarcinoma
A Phase I Study of EGF816 in Patients with Lung Cancer Containing the EGFR T790M Mutation
[Protocol 14-112]
Riely, Gregory
  • Lung Cancer, Non-Small Cell
Calypso-Based Deep Inspiration Breath Hold Radiation Treatment for Lung Cancer
[Protocol 13-174]
Rimner, Andreas
  • Lung Cancer
A Study Assessing the Predictive Value of Tumor Hypoxia (Low Oxygen Supply) in Patients with Non-Small Cell Lung Cancer
[Protocol 13-186]
Rimner, Andreas
  • Lung Cancer, Non-Small Cell
A Phase I Study of Stereotactic Body Radiation Therapy for Inoperable Locally Advanced Non-Small Cell Lung Cancer
Newly Diagnosed
[Protocol 13-113]
Rimner, Andreas
  • Lung Cancer, Non-Small Cell